Ann: Appendix 4C - Quarterly Report & Company Update, page-15

Yes spoke with company today - more just touching base to confirm some of information in quarterly etc...and process from here..

In short reiterated that directors are some of top largest 3 shareholders, believe they have cash resources to fund completing the current human and cannine trials as they live on oily rag in terms of costs (only 1 employee, serviced office box, economy travel b/w perth and sydney etc given the directors are heavily invested and aligned with shareholder interests....and nice cash boost of $550k from largest customer of Epichem

Problems with cannines with owners truing to get soft gel capsules into the dogs who don't understand like humans they are sick as even with soft gel not pleasant....

About patience as making every effort to get things done and just reiterated stuff we know.

Prize very big so case of patience but they are doing everything they can do complete the first stage of lower dosage and then move onto higher dosage trials where real fun begins...

What people need to remember is we have a major japanese listed pharma as partner for human trials behind the scenes so that in itself is fairly positive affirmation of potential of PPL given the due diligence they would have done....something that seems to have escaped the market...